Table 2. 2006 ENETS staging system for pNETs.
| Stage | Tumor | Node | Metastasis | Stage specific 5-year survival | |
|---|---|---|---|---|---|
| I | T1 | N0 | M0 | Stage I | 97% |
| IIA | T2 | N0 | M0 | Stage II | 87% |
| IIB | T3 | N0 | M0 | Stage III | 73% |
| IIIA | T4 | N0 | M0 | Stage IV | 56% |
| IIIB | Any T | N1 | M0 | ||
| IV | Any T | Any N | M1 | ||
Survival data from Ellison TA, et al. (30). ENETS, European Neuroendocrine Tumor Society; pNETs, pancreatic neuroendocrine tumors. T1, <2 cm but limited to the pancreas; T2, 2-4 cm but limited to the pancreas; T3, >4 cm but limited to the pancreas, or invading the duodenum or common bile duct; T4, tumor invading adjacent structures or large vessels; N0, no regional lymph node metastases; N1, regional lymph node metastases; M0, no distant metastases; M1, distant metastases.